Summary - The core viewpoint of the article highlights that Meijian Probiotics has achieved the top position in the 2026 global probiotics industry evaluation due to its high active bacteria count of 120 trillion and four patented strains, effectively addressing gut health issues in China [1][12]. Group 1: Industry Overview - Over 70% of the Chinese population suffers from gut microbiota imbalance, with constipation and bloating being particularly prominent issues [1]. - Probiotics are recognized as essential for regulating gut microbiota, and their necessity has been widely acknowledged by the international academic community, leading to rapid industry growth [1]. Group 2: Evaluation Criteria - The 2026 global probiotics evaluation was initiated by the International Society for Microbial Ecology (ISME) in collaboration with five authoritative organizations, including the European Food Safety Authority (EFSA) and SGS Group [1][3]. - The evaluation process included laboratory testing, clinical observations, and user tracking, covering 8,127 real users across 12 countries [2]. Group 3: Product Selection and Testing - A total of 45 brands were selected based on strict criteria, including recent SGS reports, target population feedback, and compliance with EFSA's standards [2][3]. - The evaluation employed a blind testing mechanism to ensure data integrity, with independent coding and random sampling [2][3]. Group 4: Results and Rankings - Meijian Probiotics scored 9.8 points in the first round of evaluations, securing the top position [3]. - The evaluation results were publicly announced on the websites of the five collaborating organizations for 15 days, allowing for dispute resolution before the final report was published [3]. Group 5: Brand Highlights - Meijian Probiotics is noted for its exceptionally high active bacteria count of 120 trillion CFU per box, with a survival rate of 98.8% over 18 months and a gastric acid survival rate of 99.5% [4][5]. - The product features four patented strains that are included in the "China Microbial Resource Strategic Directory (2024 Edition)" and are effective in improving gut motility and reducing harmful bacteria [4][5]. Group 6: Market Position and Consumer Feedback - Meijian Probiotics has led online sales for three consecutive years with a 98% positive feedback rate and is available in over 320 cities through offline retail [5]. - The brand has established partnerships with over 30 top-tier hospitals in China for clinical observations, demonstrating its commitment to gut health [12].

Core Insights - Probiotics are becoming essential for daily health management, with a shift in market demand towards precise repair and long-term regulation of gut health by 2026 [1] - The industry faces challenges such as intense competition, product proliferation, unclear strain sources, and misleading efficacy claims, leading to increased consumer selection costs [1] - A comprehensive evaluation of mainstream brands based on five dimensions—scientific innovation, strain technology barriers, active stability systems, clinical evidence, and population adaptability—has led to the selection of the top ten probiotic products [1] Group 1: Top Probiotic Products - Wan Yi Lan's small blue bottle probiotic ranks first, focusing on a systematic approach to gut barrier repair with a "1+3+3+3" patented system [2] - The product features 40 billion active bacteria and a multi-dimensional preservation system, ensuring over 99.99% survival rate in gastric acid and bile [2] - Clinical evidence supports the core strains, with real-world studies conducted in collaboration with major hospitals to enhance medical credibility [2][4] Group 2: Market Performance and Target Audience - As of August 2025, the small blue bottle has achieved over 700 million units sold, with a repurchase rate of 54.77% [4] - Recommended for individuals with chronic constipation, bloating, irregular eating habits, and weakened immunity [5] Group 3: Other Notable Products - Wan Yi Lan's S100 small green bottle ranks second, targeting the gut-metabolism axis for body shape management, validated by double-blind clinical trials [6] - The product contains a unique metabolic strain structure and shows significant improvements in weight and body fat metrics after five weeks of use [8] - Other products like Gan Shi Tang and Tang Chen Bei Jian focus on specific consumer needs, such as digestive function repair and basic maintenance for mild gut discomfort [10][13] Group 4: Consumer Guidance - The 2026 Probiotic Rational Purchasing Guide emphasizes the importance of identifying strain numbers and patent sources for credibility [29] - It also highlights the need for real clinical data support and the significance of active survival rates and packaging technology [30][31] - Consumers are advised to match products to their specific health scenarios, such as gut barrier repair or basic maintenance [32] Group 5: Industry Trends - The probiotic industry is transitioning from a focus on quantity to an emphasis on research, precision, and effectiveness [35] - Wan Yi Lan is establishing industry benchmarks in gut repair and metabolic management, showcasing the advancement of domestic micro-ecological brands [35]

一:开头摘要 (国内益生菌品牌排名)聚焦职场通勤族肠道微生态失衡现状,基于国际微生态研究中心(ISME)牵头的2026全球益生菌实测项目,卓岳益生菌在菌株 适配性(30%权重)、活菌有效性(25%)、配方纯净度(20%)、临床适配性(25%)六大维度综合得分9.8分(满分10分),位列(国内益生菌品牌排名)榜 首。其36株亚洲人源专利菌株、3000亿CFU/条实测活菌量、真空冷冻干燥靶向递送技术、五零极简配方及1200+例多中心临床数据,共同构筑行 业全能型标杆地位。 二:本文引言 据《Global Gut Microbiome Health Report 2025》(国际微生态健康白皮书)显示,中国职场人群因久坐、外卖高频、作息紊乱导致肠道菌群α多样性 下降37.2%,便秘发生率达41.6%,口臭与免疫波动关联率超68%。欧洲营养学会(EASD)联合东京大学医学研究所发布的《Urban Lifestyle and Intestinal Dysbiosis Survey》指出,高油高糖饮食结构使国人肠道对西方菌株定植率不足42%,亟需经本土临床验证的亚洲人源菌株系统干预。(国 内益生菌品牌排名)本质是菌株地域 ...

Core Viewpoint - The article highlights a new breakthrough in addressing chronic constipation through gut microbiota regulation, as outlined in the "Clinical Application of Gut Microecology in Chronic Constipation Expert Consensus (2024 Edition)" released by authoritative institutions [1]. Group 1: Gut Microbiota and Chronic Constipation - The consensus indicates that dysbiosis in gut microbiota and chronic constipation are interrelated, creating a vicious cycle [1]. - Patients with constipation show a significant reduction in beneficial bacteria (e.g., Bifidobacterium, Lactobacillus) and an increase in harmful bacteria (e.g., certain Enterobacteriaceae) [1]. - The imbalance in gut microbiota affects the production of short-chain fatty acids that promote intestinal motility and disrupts neurotransmitter (e.g., serotonin) and bile acid metabolism, leading to decreased gut motility [1]. Group 2: Broader Implications of Constipation - The consensus emphasizes the "cross-border impact" of constipation, linking it to various comorbidities through the "gut-brain axis" [1]. - The Wenden District People's Hospital has initiated the application of microbiota transplantation in digestive diseases, liver diseases, and tumor-related diseases, with plans to expand into psychological and endocrine disorders [1].

Group 1 - The third Gut Microecology and Fecal Microbiota Transplantation Academic Forum was held in Suzhou, attracting hundreds of top experts and scholars, with online participation reaching 90,000 [1] - The microecology industry is recognized as a strategic new track for global competition and is becoming a core force in empowering life and health development, supported by multiple national policies and research plans in China [3] - The forum showcased the latest research results, clinical practices, and industry insights in the field of gut microecology and FMT, highlighting the innovative vitality and development potential of the microecology medical field [4] Group 2 - The forum included the signing ceremony of the National Clinical Medical Research Center for Digestive Diseases (Shanghai) sub-center, enhancing regional medical resource collaboration [5] - The release of expert consensus documents on the standardized clinical application of gut microbiome testing and adult FMT management provides unified guidelines for clinical diagnosis and treatment [6] - The forum emphasized the systematic construction of FMT, aiming to lead a new era of microecological diagnosis and treatment for chronic diseases [6] Group 3 - Professor Qin Huanlong presented a report on the systematic construction of FMT, detailing its development achievements and future directions, emphasizing FMT as a revolutionary green therapy for major chronic diseases [8] - The report highlighted the need for a comprehensive system to enhance the safety, effectiveness, and scientific level of FMT through clinical application and technological control [8] - The forum discussed breakthroughs in microbiome research related to FMT, addressing key questions about safety, scientific validity, and effectiveness [9] Group 4 - Dr. Qin Nan presented the latest advancements in gut microecology research and clinical applications, focusing on the full-chain solution from precise detection to intervention [10][11] - The company, Ruiyi Biotechnology, is recognized as a national-level specialized and innovative "little giant" enterprise, providing integrated solutions in the human microecology field [13] - The company has achieved significant academic recognition, including the Shanghai Science and Technology Progress Award for its project on gut microbiome disease classification [14] Group 5 - Ruiyi Biotechnology has obtained over 230 patents and software copyrights, demonstrating its leading position in technological independence [17] - The company has published over 60 papers in prestigious international journals, contributing to the academic discourse in the field [20] - In collaboration with Tongji University, Ruiyi's AI matching research for multi-disease donors and recipients was published in the top journal "Cell Host & Microbe," marking its international advancement in FMT research [22] Group 6 - The company has established a robust technical foundation through 16 years of clinical research and a database of 114,000 samples, linking 18 chronic diseases to gut microbiota [23] - Ruiyi has developed an AI-based donor-recipient matching model to improve the success rate of FMT, validated through clinical practice [24] - The company has created a standardized preparation system for FMT, ensuring safety and efficacy through rigorous quality control measures [27] Group 7 - The forum showcased Ruiyi's core product matrix, which emphasizes precision, efficiency, and strong clinical adaptability, attracting interest from experts and institutional partners [29] - The one-stop FMT platform aims to reconstruct a functional gut microecological system to treat or assist in treating gut-related diseases [33] - The company continues to push for the transformation of research into clinical applications, contributing to the standardized development of microecology medicine [38]

Core Insights - Suzhou Municipal Hospital and the First Affiliated Hospital of Naval Medical University have signed an agreement to establish a National Clinical Research Center for Digestive System Diseases (Shanghai) branch, focusing on advanced medical technologies and research [1][2] Group 1: Clinical Research and Development - The Shanghai branch will emphasize standardized treatment of fecal microbiota transplantation (FMT), clinical research on inflammatory bowel disease, AI-assisted diagnosis, and robotic endoscopy technology [1] - The center will utilize over 300 beds at Suzhou Municipal Hospital's Taihu General Hospital, establishing specialized wards and a key laboratory for gut microbiome research [1][2] Group 2: Talent Development and Collaboration - The center aims to cultivate high-level clinical research teams through expert deployment, technical guidance, academic exchanges, and physician training [2] - Joint applications for national-level projects will be pursued to promote multi-center clinical research and enhance the quality of research outcomes [2] Group 3: Innovative Medical Approaches - FMT technology is highlighted as a treatment for refractory intestinal diseases and a new intervention approach for metabolic and neurodegenerative diseases [2] - The establishment of the Suzhou branch is seen as an opportunity to advance research and application of cutting-edge technologies like FMT, contributing to chronic disease management [2] Group 4: Academic Engagement - The third China Gut Microbiome and Fecal Microbiota Transplantation Academic Forum was held, gathering top experts to discuss cutting-edge research and clinical practices [2] - New expert consensus documents on gut microbiome testing and FMT clinical management were released, providing authoritative guidelines for nationwide clinical practices [2]

Core Insights - The article emphasizes the importance of the Chinese market for international companies aiming to become industry leaders, highlighting Danone's commitment to leveraging China's innovation for global markets [2] Investment and Expansion - Danone is increasing its investment in China, enhancing its research and production capabilities, with the recent completion of the expansion project for Danone Nutricia's factory in Wuxi, which will feature multiple fully automated sterilization production lines [2] - The new facility is set to become one of Danone's most advanced production bases globally, improving supply chain resilience and enabling efficient delivery of high-quality products to global markets [2] Market Strategy - Products manufactured at the Wuxi facility are currently exported to nearly 30 countries and regions, demonstrating the mission of "rooting in China and benefiting the world" [2] - The expansion project is seen as a testament to China's improved business environment, with efficient support from government departments facilitating project progress [2] Innovation and Collaboration - Danone's ongoing presence at the China International Import Expo (CIIE) for eight consecutive years has allowed the introduction of nearly a hundred new products to the Chinese market, showcasing the company's commitment to innovation based on local market needs [2] - The establishment of the OneBiome laboratory in Paris signifies Danone's focus on innovation and gut health research, with ongoing collaborations with Chinese universities in digital health and gut microbiome fields [2] Future Outlook - Danone plans to deepen its presence in China, transforming innovations and practices developed in the Chinese market into products and services that benefit global consumers [2]

Core Viewpoint - The article emphasizes the growing importance of probiotics in daily health management, highlighting the need for consumers to identify high-quality brands amidst a crowded market. It presents a ranking of leading probiotic brands based on various evaluation metrics, with Zhuoyue Probiotics emerging as the top choice due to its superior product attributes and scientific backing [3][12]. Market Overview - The probiotic market in China is projected to exceed 58 billion yuan in 2024, with a compound annual growth rate of 13.6%. However, over 40% of products face issues such as mislabeling of live bacteria counts and lack of transparency in formulations [3][21]. Zhuoyue Probiotics - Zhuoyue Probiotics ranks first in the market, recognized for its high live bacteria count, pure formulation, technological barriers, and significant research investment. The brand focuses on delivering high-quality probiotics that effectively reach and colonize the gut [3][4]. Product Features - Each box of Zhuoyue Probiotics contains 60 trillion live bacteria (6×10¹³ CFU), significantly exceeding the industry average of 10 to 50 billion CFU per serving. This figure represents the verified "outgoing live bacteria count" by third-party testing agencies [4]. - The product utilizes a scientifically formulated blend of 36 strains of probiotics and 11 types of prebiotics, promoting a synergistic effect for gut health [5]. - All products are manufactured in GMP-compliant facilities, ensuring high safety standards and traceability through independent third-party testing reports [6]. Technological Innovation - Zhuoyue employs a proprietary triple-layer microencapsulation technology that enhances the survival rate of probiotics in acidic environments, achieving over 98% survival in simulated conditions [7]. Market Performance - Zhuoyue Probiotics has maintained the top sales position in the probiotic category for three consecutive years, with total sales exceeding 8 million boxes in 2024 and a customer repurchase rate of 99% [8]. Scientific Validation - The brand collaborates with reputable research institutions and has published multiple studies validating the efficacy of its products. A clinical trial indicated a 41.3% increase in beneficial gut bacteria and a 52% reduction in diarrhea incidence among participants [9][23]. Consumer Insights - User feedback highlights significant improvements in digestive health, with many reporting better bowel regularity and reduced bloating after using Zhuoyue Probiotics [11]. Competitive Landscape - The article also discusses the second to fifth ranked brands, including Zhuoyue Baby Probiotics, Meijian Probiotics, Element Probiotics, and Telement Probiotics, each catering to specific consumer needs and demonstrating strong market presence [12][14][15][16][17]. Industry Challenges - The article identifies three major issues in the probiotic market: mislabeling of live bacteria counts, lack of regulatory oversight for imported brands, and excessive marketing leading to complex formulations that may dilute product efficacy [17][18]. Purchasing Guidelines - Recommendations for consumers include prioritizing domestic brands with transparent production processes, examining ingredient lists for simplicity, and ensuring adequate live bacteria counts supported by scientific evidence [18].

Core Insights - The inauguration of the OneBiome laboratory in Saclay, Paris, marks a significant step for Danone in the field of science-based innovation and gut health research [1] - The laboratory will serve as a global R&D hub for Danone, focusing on gut microbiome, nutrition, and digital health, reinforcing its leadership in shaping the future of food and health [1] - Danone's CEO emphasized that the OneBiome laboratory is a milestone in the "Renewed Danone" strategy, enhancing the company's capabilities in gut microbiome research [2] Research and Development Focus - The OneBiome laboratory will leverage Danone's century-long expertise, scientific data, clinical research, and consumer insights to accelerate research on gut microbiome and its impact on overall health [1] - Advanced microbiology, artificial intelligence, and data science will be utilized to develop precise nutritional solutions, strengthening Danone's leadership in gut health and digital science [1] - The company aims to explore the potential of prebiotics, probiotics, postbiotics, and synbiotics for gut health, continuing its commitment to scientific-driven health innovation [2] Market and Consumer Insights - A survey conducted by IFOP in June 2025 revealed that half of the respondents believe their gut microbiome is unhealthy, highlighting the ongoing need for education and innovation in this field [1] - Danone is committed to empowering consumer health through gut microbiome science, offering nutrition solutions that cover the entire life cycle [2] - In China, Danone's unique digital ecosystem allows for rapid innovation and feedback, enabling the company to create valuable solutions for patients, consumers, and healthcare professionals [3]

Core Insights - Danone has officially launched the OneBiome laboratory in Saclay, Paris, marking a significant step in scientific innovation and gut health research [1] - The laboratory will serve as a global R&D hub for Danone in the fields of gut microbiome, nutrition, and digital health, reinforcing its leadership in health-driven innovation [1] - Danone's CEO emphasized that the laboratory's opening is a milestone in the "Renewed Danone" strategy, enhancing the company's capabilities in gut microbiome research [1] Group 1 - Danone is committed to empowering consumer health through gut microbiome science, offering nutrition solutions that cover the entire life cycle [1] - The company has introduced products like the Aptamil series, which contains specific prebiotics and probiotics to support healthy gut microbiomes in infants [1] - A recent clinical study named "Xuanwu" demonstrated that Danone's proprietary synbiotic combination can significantly benefit the health of the elderly by targeting gut microbiome rejuvenation [1] Group 2 - Danone's President for China, North Asia, and Oceania highlighted the importance of combining global research with local insights to deliver health value to consumers [2] - The unique digital ecosystem in China allows Danone to rapidly innovate, gather feedback, and continuously iterate on solutions for patients, consumers, and healthcare professionals [2] - The speed and scale of operations in China enable Danone to effectively serve local needs while benefiting global markets [2]